3190 results for «996»

Filter By

3190 results

Introducing the next era of coronary intravascular lithotripsy: an aero-volution in calcium modification

27 Feb 2026 – From Euro4C Annual Meeting

Explore the next era of coronary intravascular lithotripsy featuring innovative technology for calcium modification. This session covers the unique mechanism of action, practical application in complex cases, and recent clinical evidence supporting its safety and efficacy.

Introducing next era of coronary intravascular lithotripsy: aero-volution in calcium modification

Hot topics and evidence on structural interventions in 2025 and 2026

14 Feb 2026 – From PCR Tokyo Valves 2026

Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...

Hot topics and evidence on structural interventions in 2025 and 2026

Novel Hertz Contact intravascular lithotripsy: calcium fragmentation with zero trade-offs

27 Feb 2026 – From Euro4C Annual Meeting

This session introduces the novel Hertz Contact intravascular lithotripsy system, designed for effective calcium fragmentation without trade-offs. It covers lesion types amenable to treatment, system mechanism, optimization tips, and discusses real-world cases along with supporting clinical trial evidence.

Novel Hertz Contact intravascular lithotripsy: calcium fragmentation with zero trade-offs

Prevention and management of TAVI complications

14 Feb 2026 – From PCR Tokyo Valves 2026

This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...

Prevention and management of TAVI complications

Primary mitral TEER in small anatomy - LIVE case

15 Feb 2026 – From PCR Tokyo Valves 2026

An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).

One Pascal ACE device was implanted.

LIVE Educational Case from Nagoya...

Primary mitral TEER in small anatomy - LIVE case

Guidelines update

15 Feb 2026 – From PCR Tokyo Valves 2026

This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...

Guidelines update

Future devices and techniques for structural heart disease

15 Feb 2026 – From PCR Tokyo Valves 2026

This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.

Future devices and techniques for structural heart disease

INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes

03 Sep 2024

Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.

Daniele Giacoppo

Author

Daniele Giacoppo
INFINITY-SWEDEHEART

TAILORED-CHIP: Tailored antiplatelet therapy for complex high-risk PCI

29 Aug 2025

Nicola Ryan provides her take on the results of TAILORED-CHIP presented by Duk-Woo Park at the ESC Congress 2025 in Madrid.

Nicola Ryan

Author

Nicola Ryan
TAILORED-CHIP: Tailored Antiplatelet Therapy for Complex High-Risk PCI

A randomized, placebo-controlled trial of chronic total occlusion PCI in stable angina - ORBITA-CTO trial

03 Apr 2026

Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...

John Davies

Author

John Davies
Kalaivani Mahadevan

Author

Kalaivani Mahadevan
Sarosh Khan

Author

Sarosh Khan
ORBITA-CTO: Chronic total occlusion PCI in stable angina
Didn’t find what you were looking for?